Shares in the US digital health company Hims & Hers rose sharply after the telehealth provider struck a landmark agreement with Danish pharmaceutical giant Novo Nordisk to distribute blockbuster weight-loss medicines through its online platform. The deal ends a months-long dispute between the two companies over copycat versions of popular obesity drugs and signals a new phase in the rapidly expanding digital obesity treatment market.
The partnership will allow patients using the Hims & Hers telehealth service to access Novo Nordisk’s approved treatments, including Wegovy and Ozempic through online consultations and prescriptions. The agreement has already had a significant impact on the market, with Hims & Hers shares surging by more than 40 per cent following the announcement. The deal marks a dramatic turnaround after Novo Nordisk previously sued the telehealth company over the marketing of compounded versions of semaglutide-based weight-loss medicines.
From legal dispute to strategic partnership
The two companies had been locked in a dispute earlier in 2026 after Hims & Hers began offering compounded or “copycat” formulations of semaglutide to patients through its digital platform. Novo Nordisk argued these versions infringed its patents and could mislead consumers into believing they were equivalent to the company’s approved medicines. Under the new agreement, the telehealth provider will stop promoting compounded GLP-1 medicines and instead provide access to Novo Nordisk’s officially approved drugs at the manufacturer’s self-pay prices.
In return, Novo Nordisk has agreed to drop its legal action against the company, effectively ending the dispute and opening a new distribution channel for its treatments. The drugs involved are based on semaglutide, a GLP-1 receptor agonist originally developed to treat type 2 diabetes but now widely used to support long-term weight management.
Telehealth reshaping access to obesity treatment
The partnership highlights how telehealth companies are increasingly becoming gateways to high-demand pharmaceutical therapies. Platforms like Hims & Hers combine remote consultations, prescription services and home delivery of medicines, allowing patients to access treatments without visiting a traditional clinic. This digital-first model has grown rapidly in the United States, particularly for conditions such as obesity, mental health and sexual health. Hims & Hers began as a provider of hair-loss and erectile dysfunction treatments but has expanded into broader healthcare services including mental health and weight management.
Analysts say the new agreement could help shift the weight-loss drug market away from a regulatory “grey zone” of compounded medicines and toward approved branded treatments supplied through licensed healthcare providers. However, some experts caution that relying on branded drugs could increase treatment costs and reduce the affordability that initially attracted many telehealth users.
Implications for UK healthcare
The growing global demand for GLP-1 weight-loss medicines is also influencing healthcare systems in the United Kingdom. The NHS already prescribes semaglutide-based therapies for both type 2 diabetes and certain cases of obesity, though access is tightly controlled due to cost pressures and supply constraints. Under current guidance from the National Institute for Health and Care Excellence (NICE), treatments such as Wegovy can be offered to adults with obesity who meet specific clinical criteria and typically for a limited duration as part of a wider weight-management programme. Demand for these medicines has surged worldwide, creating shortages and raising questions about how health systems should prioritise access. For the NHS, the rapid expansion of commercial telehealth platforms abroad provides both an opportunity and a cautionary example.
Digital healthcare models similar to Hims & Hers are emerging in the UK, where remote consultations and app-based prescribing are becoming more common through services integrated with NHS primary care or private providers. Health policy analysts say telehealth could play a role in expanding access to weight-management services while reducing pressure on overstretched GP practices. However, they warn that strong regulation will be needed to ensure patient safety, accurate prescribing and equitable access to expensive medicines.
A growing global obesity treatment market
The agreement also reflects the enormous commercial potential of the obesity drug market. Novo Nordisk’s weight-loss treatments have become some of the most sought-after medicines globally, driving significant revenue growth for the Danish pharmaceutical company. Pharmaceutical rivals, including Eli Lilly, are racing to develop competing therapies as demand for obesity treatments continues to grow. For digital health companies, partnerships with pharmaceutical manufacturers could become an increasingly important strategy for accessing blockbuster medicines while avoiding legal disputes over compounded alternatives.
Digital healthcare and the future of obesity treatment
The Hims & Hers–Novo Nordisk deal illustrates how digital health platforms, pharmaceutical companies and healthcare systems are beginning to converge in the treatment of chronic conditions such as obesity. While the NHS operates under a very different funding model from the US healthcare system, the rapid rise of telehealth-driven prescribing and digital treatment pathways is likely to influence how weight-management services evolve in the UK. As demand for GLP-1 medicines continues to grow, policymakers will face difficult questions about how to balance affordability, access and clinical effectiveness, both within the NHS and across the wider digital healthcare ecosystem.
